Loading clinical trials...
Loading clinical trials...
The main goal of this study is assess the effectiveness of a PtDA for patients with GAD.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Servicio Canario de Salud
NCT05271409 · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
NCT06804525 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more
NCT07429578 · Generalized Anxiety Disorder (GAD), Chronic Insomnia
NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more
NCT05467683 · Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, and more
Servicio de Evaluación del Servicio Canario de la Salud
Santa Cruz de Tenerife
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions